Literature DB >> 27756664

Endoscopic Endonasal versus Microsurgical Transsphenoidal Approach for Growth Hormone-Secreting Pituitary Adenomas-Systematic Review and Meta-Analysis.

Kevin Phan1, Joshua Xu2, Rajesh Reddy3, Piyush Kalakoti4, Anil Nanda4, Jacob Fairhall3.   

Abstract

BACKGROUND: The pituitary adenoma causing acromegaly is typically resected through a transsphenoidal approach and visualized with an operating microscope or endoscope. We undertook a systematic review and meta-analysis examining the clinical efficacy of endoscopic and microsurgical approaches.
METHODS: Relevant studies using either endoscopic or microscopic transsphenoidal approaches for growth hormone pituitary adenomas were identified until February 2016. Data were extracted and analyzed according to predefined clinical end points.
RESULTS: We identified 31 studies, in which 950 patients underwent endoscopic transsphenoidal resection and 2137 patients underwent microsurgical transsphenoidal resection. Patients undergoing microsurgery were less likely to present with hypothyroidism (10.7% vs. 19.1%, P = 0.033, 462 vs. 156 patients) and less likely to have macroadenomas (66.9% vs. 83.8%, P ≤ 0.001, 1484 vs. 884 patients); adenomas with cavernous sinus invasion (21.3% vs. 44.4%, P = 0.036, 592 vs. 558 patients); and a lower mean tumor volume (17.84 vs. 20.54 mm3, P = 0.012, 158 vs. 248 patients). Patients treated via the endoscopic approach were more likely to achieve remission for noninvasive macroadenomas (83.8% vs. 66.9%, P ≤ 0.001, 115 vs. 365 patients). Sinusitis (15.6% vs. 2.6%, P < 0.001, 241 vs. 295 patients) and intraoperative cerebrospinal fluid leak (21.6% vs. 1.0%, P = 0.022, 697 vs. 127 patients) were more common in patients treated endoscopically, and meningitis (0.7% vs. 1.7%, P = 0.027, 511 vs. 1513 patients) was more common in patients undergoing a microsurgical approach.
CONCLUSIONS: Our study shows the clinical utility of the endoscopic approach and demonstrates potential benefits including increased remission rates with noninvasive macroadenomas and a lower rate of meningitis.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acromegaly; Adenoma; Endoscopic; Meta-analysis; Microsurgical; Pituitary

Mesh:

Year:  2016        PMID: 27756664     DOI: 10.1016/j.wneu.2016.10.029

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Evolution of Technique in Endoscopic Transsphenoidal Surgery for Pituitary Adenoma: A Single Institution Experience from 220 Procedures.

Authors:  Ake Hansasuta; Siriwut Pokanan; Pritsana Punyawai; Wattana Mahattanakul
Journal:  Cureus       Date:  2018-01-01

2.  Predictors of postoperative biochemical remission in lower Knosp grade growth hormone-secreting pituitary adenomas: a large single center study.

Authors:  S Zhang; J Chen; Y Zhu; H Wang; Z Mao; S Yao; F Akter; Z Wang; B Hu; D Zhu; C Duan; W Chen
Journal:  J Endocrinol Invest       Date:  2022-09-20       Impact factor: 5.467

3.  Safety and efficacy of repeat radiosurgery for acromegaly: an International Multi-Institutional Study.

Authors:  Clayton E Alonso; Adomas Bunevicius; Daniel M Trifiletti; James Larner; Cheng-Chia Lee; Fu-Yuan Pai; Roman Liscak; Mikulas Kosak; Hideyuki Kano; Nathaniel D Sisterson; David Mathieu; L Dade Lunsford; Jason P Sheehan
Journal:  J Neurooncol       Date:  2019-09-20       Impact factor: 4.130

Review 4.  Outcome of endoscopic vs microsurgical transsphenoidal resection for Cushing's disease.

Authors:  Nidan Qiao
Journal:  Endocr Connect       Date:  2018-01       Impact factor: 3.335

5.  Outcomes of endoscopic and microscopic transsphenoidal surgery on non-functioning pituitary adenomas: a systematic review and meta-analysis.

Authors:  Shi-Yuan Yu; Qiu Du; Si-Yuan Yao; Ke-Nan Zhang; Jian Wang; Zhe Zhu; Xiao-Bing Jiang
Journal:  J Cell Mol Med       Date:  2018-01-04       Impact factor: 5.310

6.  Effects of Staged Nursing Care on Neuroendoscopic Transsphenoidal Pituitary Adenoma Resection and Postoperative Complications.

Authors:  Yaya Fei; Jiajia Zhang; Yudan Gu
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-05       Impact factor: 2.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.